Adults 19 to 70, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Urinary Oxalate ExcretionPrimary· 3 days on the fixed diet
Mean Urinary oxalate excretion from three 24 hour urine collections on the fixed diet (mg/day)
Group
Value
95% CI
Normal Individuals
24
± 10
Urinary Glycolate ExcretionSecondary· 3 days on fixed diet
mean of three 24-hr urinary glycolate collected on the fixed diet (mg/day)
Group
Value
95% CI
Normal Individuals
32
± 14
Urinary Creatinine ExcretionSecondary· 3 days on the fixed diet
mean of there 24hr urinary creatinine excretion on the fixed diet ( g/day)
Group
Value
95% CI
Normal Individuals
1.47
± 0.58
Sponsor's own description
The goal of this study is to determine if obesity is associated with increased endogenous oxalate synthesis as assessed by urinary oxalate excretion, which is a known risk factor for calcium oxalate kidney stones.
The study will recruit adult participants without history of kidney stones. Participants will
* Ingest fixed diets containing low amounts of oxalate for 4 days
* Collect 24-hr urine samples during the fixed diet
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis
· NA
· not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis
· NA
· withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis
· NA
· not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine
· Phase 2
· not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit
· Phase 2
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03808090.